4 news items
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
KA
15 May 24
trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance of Kineta's product candidates; Kineta's
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
KA
8 Apr 24
clinical response data and the durability of patient benefit emerging from the study. The safety profile of KVA12123 to date has been remarkable
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
KA
21 Mar 24
salaries and benefits of $1.2 million from increased headcount to support public company responsibilities and higher stock-based compensation of $1.0
KVA12123 Clears Additional Cohorts In Monotherapy And In Combination Therapy Arms In The Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
KA
12 Mar 24
with the progress of the study, the initial clinical response data, and the durability of patient benefit emerging from the study. We continue to be encouraged
- Prev
- 1
- Next